Drug Type Oncolytic virus |
Synonyms G 207, G207, HSV G207 |
Target |
Mechanism RNR inhibitors(Ribonucleotide reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 2 | - | 01 Dec 2001 | |
Recurrent Malignant Glioma | Phase 2 | - | 01 Dec 2001 | |
Primitive Neuroectodermal Tumors | Phase 1 | US | 01 May 2016 | |
Supratentorial Neoplasms | Phase 1 | US | 01 May 2016 | |
Glioma | Phase 1 | US | 01 May 2005 | |
Glioma | Phase 1 | US | 01 May 2005 |
Phase 1 | 12 | sowaaeqgou(niqrawlgcs) = No serious adverse events were attributed to G207 by the investigators ghzkdhrynj (nbsgftdqlx ) View more | Positive | 29 Apr 2021 | |||
Phase 1 | 9 | qtwjfnopfo(xlvcaxmpec) = 20 serious adverse events occurred in this study, only 3 were possible/probable related to G207/irradiation dhvydmsbkn (dajdrhwpjg ) | Positive | 20 May 2009 | |||
(Irradiation) |